Local Treatment of Meniscal Lesions with Vascular Endothelial Growth Factor

Kopf, Sebastian; Birkenfeld, Falk; Recker, Roland; Petersen, Wolf; Stärke, Christian; Wruck, Christoph Jan; Tohidnezhad, Mersedeh; Varoga, Deike; Pufe, Thomas
November 2010
Journal of Bone & Joint Surgery, American Volume;11/17/2010, Vol. 92-A Issue 16, p2682
Academic Journal
Background: The healing potential in the avascular regions of the meniscus is very limited, and improving the vascularity might be a reasonable way to improve healing. Vascular endothelial growth factor (VEGF) is one of the most potent proangiogenetic factors. We hypothesized that the local application of VEGF165 would (1) improve the healing of a lesion in the avascular region of the meniscus, (2) induce angiogenesis in both the avascular and vascular regions, and (3) increase the amounts of VEGF mRNA and VEGF. Methods: In eighteen sheep, the medial menisci were cut longitudinally in the avascular region and were sutured. Three groups were established depending on the suture material: (1) uncoated Ethibond, (2) Ethibond coated with VEGF165 and its carrier Poly(D,L-Lactide) (PDLLA), and (3) Ethibond coated with PDLLA. The contralateral medial menisci served as a control group. Each of the three suture type groups included six animals. After eight weeks, the sheep were killed, and the menisci were examined macroscopically. Immunohistochemistry of Factor VIII and VEGF and real-time reversetranscription polymerase chain reaction (RT-PCR) of VEGF mRNA were performed. Additionally, the VEGF release kinetics from the VEGF/PDLLA-coated suture were evaluated in vitro. Results: In this model, VEGF did not improve meniscal healing. It did not increase angiogenesis in the avascular or vascular region, the VEGF concentration, or the amount of VEGF mRNA. VEGF release from the coated suture peaked on Day 3 and was nearly zero on Day 9. Conclusions: The local application of VEGF165 as eluted from suture did not increase meniscal angiogenesis or improve meniscal healing. In addition, there was no effect on the amount of VEGF mRNA and VEGF. The VEGF carrier (PDLLA) may have been inadequate because of the short duration of VEGF supply.


Related Articles

  • Researchers explore ways to enhance anti-VEGF therapy in AMD treatment. Bechtel, Bryan // Ocular Surgery News;8/10/2010, Vol. 28 Issue 15, p22 

    The article reports on the efforts of researchers in enhancing the efficacy of anti-vascular endothelial growth factor (VEGF) therapy in the treatment of age-related macular degeneration (AMD). Researchers have considered combination therapies in an effort to develop a therapy that may result in...

  • Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology. Loveless, Mary E.; Lawson, Deborah; Collins, Michael; Prasad Nadella, Murali V.; Reimer, Corinne; Huszar, Dennis; Halliday, Jane; Waterton, John C.; Gore, John C.; Yankeelov, Thomas E. // Neoplasia;Jan2012, Vol. 14 Issue 1, p54 

    Jak1/2 inhibition suppresses STAT3 phosphorylation that is characteristic of many cancers. Activated STAT3 promotes the transcription of factors that enhance tumor growth, survival, and angiogenesis. AZD1480 is a novel small molecule inhibitor of Jak1/2,which is a key mediator of STAT3...

  • Expression and identification of recombinant chicken vascular endothelial growth factor in Pichia pastoris and its role in the pathogenesis of tibial dyschondroplasia. Zhang, J.-P.; Deng, Y.-F.; Zhou, Z.-L.; Hou, J.-F. // Poultry Science;Dec2013, Vol. 92 Issue 12, p3214 

    Vascular endothelial growth factor (VEGF) is an essential mediator of angiogenesis and endochondral ossification. To explore the role of VEGF in avian diseases such as tibial dyschondroplasia (TD), a typical disorder of endochondral ossification, we ex-pressed and identified recombinant chicken...

  • Investigation of Antiangiogenic Tumor Therapy Potential of Microencapsulated HEK293 VEGF165b Producing Cells. Afkhami, Fatemeh; Durocher, Yves; Prakash, Satya // Journal of Biomedicine & Biotechnology;2010, p1 

    To investigate the antiangiogenic potential of encapsulated VEGF165b producing HEK293 cells, Human Embryonic Kidney 293 (HEK293) cells were stably transfected to produce VEGF165b. Then they were encapsulated in alginate - polylysine -alginate (APA) microcapsules. VEGF165b productivity and...

  • Effects of human vascular endothelial growth factor on reparative dentin formation. JUAN ZHANG; XIA LIU; WEIXIAN YU; YINGLI ZHANG; CE SHI; SHILEI NI; QILIN LIU; XIANGWEI LI; YINGJIAN SUN; CHANGYU ZHENG; HONGCHEN SUN // Molecular Medicine Reports;2016, Vol. 13 Issue 1, p705 

    It is a challenge for dentists to save dental pulp in patients with pulp disease without resorting to root canal therapy. Formation of tertiary dentin to maintain pulp vitality is a key odontoblast response to dental pulp injury. Vascular endothelial growth factor (VEGF) is the most potent...

  • The remote effects of intravitreal anti-VEGF therapy. Balta, F.; Merticariu, M.; Taban, C.; Neculau, G.; Merticariu, A.; Muresanu, D.; Badescu, D.; Jinga, V. // Journal of Medicine & Life;Oct-Dec2016, Vol. 9 Issue 4, p392 

    Objective: To study the effects of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) therapy with Avastin for wet Age-Related Macular Degeneration (AMD) on Benign Prostatic Hyperplasia (BPH)-related symptoms. Methods: An exploratory trial was conducted from August 1, 2013 to February...

  • Genetic Advancements in AMD: A Glimpse at the Future. Dunbar, Mark T. // Review of Optometry;Nov2010 Supplement to Review of Opt, p18 

    The article offers information on the genetic breakthroughs for the treatment of age-related macular degenerative disease. It discusses the development of anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of wet age-related macular degenerative disease (AMD). It also...

  • Fusion protein yields visual benefit. Charters, Lynda // Ophthalmology Times;8/1/2011, Vol. 36 Issue 15, p25 

    The article examines the administration of aflibercept or anti-vascular endothelial growth factor (VEGF) Trap-Eye: Eylea, Regeneron Pharmaceuticals at three dosing regimens and intervals in treating neovascular age-related macular degeneration (AMD). The study suggests the noninferiority of...

  • Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions. Finley, Stacey D.; Popel, Aleksander S. // JNCI: Journal of the National Cancer Institute;6/5/2013, Vol. 105 Issue 11, p802 

    Background Vascular endothelial growth factor (VEGF) is known to be a potent promoter of angiogenesis under both physiological and pathological conditions. Given its role in regulating tumor vascularization, VEGF has been targeted in various cancer treatments, and anti-VEGF therapy has been used...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics